It would possibly have been better had the placebo results not been so good ;-) .
These are top-line data ... full read-out should provide more insight (though not necessarily in a positive way). I'm banking (literally) that full results will be just as good or better. But this was an excellent start.
RHB-104 for Crohn's is also due soon, which if positive, will certainly have a dramatic effect on the share price, IMO.
News 
Market Data 
Discover 
